9,910 Shares in GSK plc (NYSE:GSK) Purchased by Catalytic Wealth RIA LLC

Catalytic Wealth RIA LLC purchased a new position in GSK plc (NYSE:GSKFree Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 9,910 shares of the pharmaceutical company’s stock, valued at approximately $367,000.

Other hedge funds have also recently added to or reduced their stakes in the company. Fiduciary Trust Co grew its stake in shares of GSK by 4.0% during the fourth quarter. Fiduciary Trust Co now owns 14,881 shares of the pharmaceutical company’s stock valued at $551,000 after purchasing an additional 569 shares during the last quarter. Hsbc Holdings PLC bought a new stake in shares of GSK during the fourth quarter valued at approximately $92,281,000. Cape Investment Advisory Inc. grew its stake in shares of GSK by 4.8% during the fourth quarter. Cape Investment Advisory Inc. now owns 6,686 shares of the pharmaceutical company’s stock valued at $248,000 after purchasing an additional 308 shares during the last quarter. Primecap Management Co. CA grew its stake in shares of GSK by 0.3% during the fourth quarter. Primecap Management Co. CA now owns 12,089,370 shares of the pharmaceutical company’s stock valued at $448,032,000 after purchasing an additional 30,600 shares during the last quarter. Finally, ProVise Management Group LLC grew its stake in shares of GSK by 63.6% during the fourth quarter. ProVise Management Group LLC now owns 117,967 shares of the pharmaceutical company’s stock valued at $4,372,000 after purchasing an additional 45,874 shares during the last quarter. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Upgrades and Downgrades

GSK has been the topic of several research analyst reports. Citigroup raised shares of GSK from a “neutral” rating to a “buy” rating in a research note on Tuesday, February 13th. Guggenheim upgraded shares of GSK from a “neutral” rating to a “buy” rating in a report on Monday, March 4th. Finally, The Goldman Sachs Group started coverage on shares of GSK in a report on Thursday. They issued a “neutral” rating and a $47.00 price objective on the stock. One investment analyst has rated the stock with a sell rating, two have given a hold rating, three have given a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, GSK presently has an average rating of “Moderate Buy” and an average price target of $47.00.

Get Our Latest Stock Analysis on GSK

GSK Stock Down 0.6 %

GSK stock traded down $0.25 during mid-day trading on Thursday, reaching $44.03. The company’s stock had a trading volume of 1,597,366 shares, compared to its average volume of 3,497,352. The company has a market capitalization of $91.25 billion, a price-to-earnings ratio of 15.95, a price-to-earnings-growth ratio of 1.33 and a beta of 0.65. GSK plc has a 12 month low of $33.33 and a 12 month high of $45.92. The business’s 50 day simple moving average is $42.71 and its 200 day simple moving average is $40.40. The company has a debt-to-equity ratio of 1.15, a quick ratio of 0.58 and a current ratio of 0.87.

GSK (NYSE:GSKGet Free Report) last released its earnings results on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, beating analysts’ consensus estimates of $0.94 by $0.15. The business had revenue of $9.34 billion during the quarter, compared to the consensus estimate of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%. As a group, research analysts anticipate that GSK plc will post 4.12 earnings per share for the current year.

GSK Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Stockholders of record on Friday, May 17th will be given a $0.3762 dividend. This represents a $1.50 dividend on an annualized basis and a dividend yield of 3.42%. The ex-dividend date of this dividend is Thursday, May 16th. This is an increase from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio (DPR) is 53.26%.

GSK Profile

(Free Report)

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.

See Also

Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GSK plc (NYSE:GSKFree Report).

Institutional Ownership by Quarter for GSK (NYSE:GSK)

Receive News & Ratings for GSK Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GSK and related companies with MarketBeat.com's FREE daily email newsletter.